摘要
目的:观察伊马替尼联合高三尖杉酯碱(HHT)治疗初诊慢性髓细胞性白血病(CML)的疗效和毒副反应。方法:33例CML患者随机分为2组,伊马替尼联合HHT治疗17例(IM+HHT组),单用伊马替尼治疗16例(IM组),观察不同时段的血液学和细胞遗传学反应率。结果:两组患者治疗3个月时的血液学缓解率和治疗6个月时的细胞遗传学反应率无显著差异,但治疗12个月时IM+HHT组的完全和部分细胞遗传学反应率高于IM组。两组间非血液学毒性和3级以上血液学毒性发生率无显著差异。结论:HHT和伊马替尼的抗CML效应有协同作用,两者联合使用可提高初诊CML患者的细胞遗传学反应率。
Objective To observe the curative effect, toxicity and side-effect of imatinib combined homoharringtonine （HHT） on newly diagnosed chronic myeloid leukemia （CML）. Methods 33 patients were randomly divided into 2 groups, the united imatinib with HHT group had 17 cases （IM ＋ HHT group） and imatinib single-use group 16 cases （IM group）. Hematologic and cytogenetic response rates at different times of treatment were observed. Results The hematologic remission rate at third month and cytogenetic remission rate at sixth month had no significant difference,but the cytogenetic remission rate at twelfth month of IM ＋ HHT group was higher than that in IM group. There were no significant differences of non-hematological toxicity and serious hematological toxicity between the two groups. Condusion There is a synergistic effect between HHT and imatinib on CML and combined use of imatinib and HHT may increase the cytogenetic remission rate of newly diagnosed CML patients.
出处
《东南大学学报（医学版）》
CAS
2009年第5期430-432,共3页
Journal of Southeast University(Medical Science Edition)
